Patents by Inventor Wayman Wendell Cheatham

Wayman Wendell Cheatham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200138912
    Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
    Type: Application
    Filed: January 7, 2020
    Publication date: May 7, 2020
    Inventors: Wayman Wendell Cheatham, Anders Hasager Boss
  • Publication number: 20170087217
    Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
    Type: Application
    Filed: December 13, 2016
    Publication date: March 30, 2017
    Inventors: Wayman Wendell Cheatham, Anders Hasager Boss
  • Publication number: 20110183901
    Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
    Type: Application
    Filed: March 31, 2011
    Publication date: July 28, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: Wayman Wendell Cheatham, Anders Hasager Boss
  • Patent number: 7943572
    Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: May 17, 2011
    Assignee: MannKind Corporation
    Inventors: Wayman Wendell Cheatham, Anders Hasager Boss
  • Publication number: 20080260838
    Abstract: A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.
    Type: Application
    Filed: April 16, 2007
    Publication date: October 23, 2008
    Applicant: MANNKIND CORPORATION
    Inventors: Mark J. Hokenson, David Brandt, Mark King, Stephanie Greene, Mary Faris, Keith Oberg, Wayman Wendell Cheatham, Cohava Gelber, Andrea Leone-Bay